1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections

BACKGROUND: SPR720 (phosphate pro-drug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for non-tuberculous mycobacterial lung disease (NTM-LD) and pulmonary tuberculosis. SPR719 has broad-spectrum activity versus clinically relevant mycobacteria in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Talley, Angela, Thurston, Archie, Moore, Grayson, Satterfield, Myriah M, Manyak, Erika L, Kumar, Vipul, Stokes, Suzanne, Dane, Aaron, Melnick, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777491/
http://dx.doi.org/10.1093/ofid/ofaa439.1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777491/
http://dx.doi.org/10.1093/ofid/ofaa439.1471

Ejemplares similares